![Mats Lundwall](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Mats Lundwall
Direktor/Vorstandsmitglied bei PHASE HOLOGRAPHIC IMAGING PHI AB
Aktive Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Jan Peter Egelberg | M | 61 | 27 Jahre | |
Patrik Eschricht | M | 60 | 6 Jahre | |
Lisa Bodily | F | - | 2 Jahre | |
Leland George Foster | M | 78 | 12 Jahre | |
Håkan Rosvall | M | 45 | 14 Jahre | |
Petter Björquist | M | 59 | - | |
Mattias Lundin | M | 56 | 4 Jahre | |
Jonas Bergkvist | M | 53 | 7 Jahre | |
Ann Christine Egelberg | F | 61 | 20 Jahre | |
Kersti Alm | F | - | - | |
Goran Dubravcic | M | 45 | 1 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Keith McCullagh | M | 80 |
Roche Innovation Center Copenhagen A/S
![]() Roche Innovation Center Copenhagen A/S Pharmaceuticals: MajorHealth Technology Roche Innovation Center Copenhagen A/S discovers and develops drugs for the treatment of oncology, metabolic diseases, and infectious diseases. The firm manufactures a pipeline of drug candidates that act selectively on disease-related ribonucleic acid to provide patients with novel treatments for both rare and common diseases. It produces pre-clinical and clinical assets for the treatment of a range of diseases including oncology, metabolic diseases, and infectious diseases. The company was founded by Matts Lundwall and Mikael Ørum on January 1, 1998 and is headquartered in Horsholm, Denmark. | 5 Jahre |
Per Gunnar Fernström | M | 74 |
Roche Innovation Center Copenhagen A/S
![]() Roche Innovation Center Copenhagen A/S Pharmaceuticals: MajorHealth Technology Roche Innovation Center Copenhagen A/S discovers and develops drugs for the treatment of oncology, metabolic diseases, and infectious diseases. The firm manufactures a pipeline of drug candidates that act selectively on disease-related ribonucleic acid to provide patients with novel treatments for both rare and common diseases. It produces pre-clinical and clinical assets for the treatment of a range of diseases including oncology, metabolic diseases, and infectious diseases. The company was founded by Matts Lundwall and Mikael Ørum on January 1, 1998 and is headquartered in Horsholm, Denmark. | - |
Bo Lennart Bruce | M | 80 |
Roche Innovation Center Copenhagen A/S
![]() Roche Innovation Center Copenhagen A/S Pharmaceuticals: MajorHealth Technology Roche Innovation Center Copenhagen A/S discovers and develops drugs for the treatment of oncology, metabolic diseases, and infectious diseases. The firm manufactures a pipeline of drug candidates that act selectively on disease-related ribonucleic acid to provide patients with novel treatments for both rare and common diseases. It produces pre-clinical and clinical assets for the treatment of a range of diseases including oncology, metabolic diseases, and infectious diseases. The company was founded by Matts Lundwall and Mikael Ørum on January 1, 1998 and is headquartered in Horsholm, Denmark. | - |
Peter Wilden | M | 67 |
Ferring Pharmaceuticals A/S
![]() Ferring Pharmaceuticals A/S Pharmaceuticals: MajorHealth Technology Ferring Pharmaceuticals A/S specializes in the development, production and marketing of pharmaceutical products. It offers products in the fields of urology, infertility, obstetrics, gynecology, gastroenterology and maternal health. The company is headquartered in Copenhagen, Denmark. | 26 Jahre |
Mikael Ørum | M | 71 |
Roche Innovation Center Copenhagen A/S
![]() Roche Innovation Center Copenhagen A/S Pharmaceuticals: MajorHealth Technology Roche Innovation Center Copenhagen A/S discovers and develops drugs for the treatment of oncology, metabolic diseases, and infectious diseases. The firm manufactures a pipeline of drug candidates that act selectively on disease-related ribonucleic acid to provide patients with novel treatments for both rare and common diseases. It produces pre-clinical and clinical assets for the treatment of a range of diseases including oncology, metabolic diseases, and infectious diseases. The company was founded by Matts Lundwall and Mikael Ørum on January 1, 1998 and is headquartered in Horsholm, Denmark. | - |
Johan Hyllner | M | 62 | - | |
Maria Hägglund Morin | F | 50 | - | |
Ingrid Linda Marie Neckmar | F | 51 | - | |
Klas Åke Thorsten Cramborn | M | 75 | 9 Jahre | |
Arne Bojesson | M | 73 | - | |
Liselotte Nilsson | F | 54 | - | |
Jorgen Wittendorff | M | - |
Ferring Pharmaceuticals A/S
![]() Ferring Pharmaceuticals A/S Pharmaceuticals: MajorHealth Technology Ferring Pharmaceuticals A/S specializes in the development, production and marketing of pharmaceutical products. It offers products in the fields of urology, infertility, obstetrics, gynecology, gastroenterology and maternal health. The company is headquartered in Copenhagen, Denmark. | 21 Jahre |
Charlotte Vedel | M | 56 |
Roche Innovation Center Copenhagen A/S
![]() Roche Innovation Center Copenhagen A/S Pharmaceuticals: MajorHealth Technology Roche Innovation Center Copenhagen A/S discovers and develops drugs for the treatment of oncology, metabolic diseases, and infectious diseases. The firm manufactures a pipeline of drug candidates that act selectively on disease-related ribonucleic acid to provide patients with novel treatments for both rare and common diseases. It produces pre-clinical and clinical assets for the treatment of a range of diseases including oncology, metabolic diseases, and infectious diseases. The company was founded by Matts Lundwall and Mikael Ørum on January 1, 1998 and is headquartered in Horsholm, Denmark. | 2 Jahre |
Statistik
Land | Beziehungen | % des Gesamten |
---|---|---|
Schweden | 17 | 70,83% |
Dänemark | 7 | 29,17% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Mats Lundwall
- Persönliches Netzwerk